EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit


This kit is intended for the qualitative detection of COVID-19 IgG antibody in human serum. It detects IgG antibody specific binding to SARS-CoV-2 Nucleocapsid protein and doesn’t detect antibody to Spike protein in human serum. It is for screening or to aid in the diagnosis of COVID-19. Patients with suspected clustering cases require diagnosis or differential diagnosis of novel coronavirus infection. The assay is validated manually, but can be adapted to an automated instrument.

​​​​​​​For In-vitro diagnostic Purpose Only


This ELISA kit is designed, developed, and produced for the qualitative measurement of the human anti-COVID-19 IgG antibody in serum. This assay utilizes the microplate based enzyme immunoassay technique.

Assay controls and 1:100 diluted human serum samples are added to the microtiter wells of a microplate that was coated with COVID-19 recombinant full length nucleocapsid protein. After the first incubation period, the unbound protein matrix is removed with a subsequent washing step. A horseradish peroxidase (HRP) labeled polyclonal goat anti-human IgG tracer antibody is added to each well. After an incubation period, an immunocomplex of "COVID-19 recombinant antigen – human anti-COVID-19 IgG antibody - HRP labeled antihuman IgG tracer antibody" is formed if there is specific coronavirus IgG antibody present in the tested specimen. The unbound tracer antibody is removed by the subsequent washing step. HRP-labeled tracer antibody bound to the well is then incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the tracer antibody bound to the antiCOVID-19 IgG on the wall of the microtiter well is proportional to the amount of the anti-COVID-19 IgG antibody level in the tested specimen.

Technical Specifications

For in-vitro diagnostic use.